Filings Set For Takeda’s Ixazomib On Phase III Data
This article was originally published in PharmAsia News
Takeda is set to file for approval worldwide of its leading oral proteasome inhibitor ixazomib in multiple myeloma on the basis of encouraging interim data from the Phase III TOURMALINE-MM1 study.
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.